IMMU

Immunomedics Announces Outcome of 2008 Annual Meeting of Stockholders - 12/03 - 11:33 AM ET

Immunomedics to Present At 50th ASH Annual Meeting - 12/02 - 08:30 AM ET

IMMU: To Present At Lazard Capital Healthcare Conference @ 17:10 ET [delayed] - 11/18 - 03:53 PM ET

BRIEF-Immunomedics Q1 results - 11/07 - 08:48 AM ET

Immunomedics Announces First Quarter Fiscal 2009 Results - 11/07 - 08:30 AM ET

IMMU: To Present At Oppenheimer Healthcare Conference @ 16:00 ET [delayed] - 11/04 - 02:23 PM ET

Immunomedics to Present At Oppenheimer 19th Annual Healthcare Conference - 10/30 - 08:30 AM ET

Immunomedics wins new US patents - 10/15 - 10:55 AM ET

Immunomedics Announces U.S. Patents Awarded for CD20 Antibody, Veltuzumab, and Reagents Used in Pretargeted Imaging and Therapies - 10/14 - 08:30 AM ET

Immunomedics Highlights Progress With Clinical Programs At R&D Day - 09/17 - 11:31 AM ET

Immunomedics to Host R&D Day - 09/08 - 08:30 AM ET

Immunomedics Announces Fiscal 2008 Results - 08/28 - 04:00 PM ET

IMMU: To Present At IBC Life Sciences DDT 2008 Conference @ 09:40 ET [delayed] - 08/04 - 08:23 AM ET

Results With Epratuzumab in Children With Acute Lymphoblastic Leukemia Published in Journal of Clinical Oncology - 08/01 - 10:30 AM ET

Immunomedics Inc signs worldwide license and collaboration agreement with Nycomed GmbH for veltuzumab - 07/15 - 01:27 PM ET

Immunomedics Climbs Over Its 50- And 200-Day Moving Averages On News Of Licensing Agreement - 07/14 - 02:45 PM ET

Immunomedics and Nycomed sign collaboration agreement - 07/14 - 11:15 AM ET

Immunomedics up in premarket on licensing pact with Nycomed - 07/14 - 09:22 AM ET

IMMU: License Agreement w/Nycomed GmbH re Veltuzumab for Non-Cancer Indications - 07/14 - 09:22 AM ET

Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications - 07/14 - 08:30 AM ET

Page 1 of 5     1  2   3   4   5      Previous  |  Next

<< Back to Stock Index